PFE Stock Risk & Deep Value Analysis
Pfizer Inc
Healthcare • Drug Manufacturers - General
DVR Score
out of 10
What You Need to Know About PFE Stock
We analyzed Pfizer Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PFE through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
PFE Risk Analysis & Red Flags
What Could Go Wrong
Pfizer's significant debt load from the Seagen acquisition, coupled with forecasted revenue and earnings declines, could strain its ability to invest in new growth areas or maintain its dividend if cost savings and new pipeline successes do not materialize quickly enough to offset patent expirations.
Risk Matrix
Overall
Moderate
Financial
Medium
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Forecasted annual revenue decline of 4.3%
- ⚠
Forecasted annual earnings decline of 3.7%
- ⚠
Increased leverage post-Seagen acquisition leading to slowed share buybacks
- ⚠
3-year average Free Cash Flow per Share declined -30.90% per annum
Upcoming Risk Events
- 📅
Q1 2026 earnings miss or weaker-than-expected forward guidance
- 📅
Pipeline failures or delays for key late-stage assets
- 📅
Increased competitive pressure or patent challenges on existing blockbusters
When to Reconsider
- 🚪
Quarterly revenue decline exceeding current forecasts by more than 5%
- 🚪
Failure of a major Phase 3 clinical trial or significant regulatory setback for a key pipeline asset
- 🚪
Announcement of a dividend cut or suspension
Unlock PFE Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Pfizer Inc (PFE) Do?
Market Cap
$161.10B
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
81,000
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Visit Pfizer Inc WebsiteInvestment Thesis
Pfizer is a mature pharmaceutical giant leveraging its robust R&D and recent strategic acquisitions (Seagen) to navigate patent cliffs and drive future growth in key therapeutic areas like oncology and vaccines. Activist investor involvement provides an additional catalyst for operational efficiency and value creation through cost savings, positioning it for potential modest appreciation and stable dividend income rather than exponential growth.
Is PFE Stock Undervalued?
Unlock the full AI analysis for PFE
Get the complete DVR score, risk analysis, and more
PFE Price Targets & Strategy
12-Month Target
$32.00
Bull Case
$35.00
Bear Case
$25.00
Valuation Basis
Based on 16.0x P/FCF applied to estimated stabilized FY26 Free Cash Flow per share of $2.00, reflecting successful cost reduction initiatives.
Entry Strategy
Consider dollar-cost averaging between $27-$29, leveraging its stable dividend yield for long-term hold.
Exit Strategy
Take profit on significant rallies above $33-35, reassess if price breaks below $26 (historical support).
Portfolio Allocation
3-5% for moderate risk tolerance due to stability and dividend; 1-2% for aggressive portfolios seeking balance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is PFE Financially Healthy?
Valuation
P/E Ratio
20.20
Forward P/E
20.80
EV/EBITDA
8.92
Price/Book
1.80
Profitability
Gross Margin
77.20%
Net Margin
12.40%
Return on Equity
8.90%
Revenue Growth
-1.70%
EPS
$0.00
Balance Sheet
Current Ratio
1.20
Cash Flow
Free Cash Flow
$11.22B
EBITDA
$7.10B
Other
Dividend Yield
6.22%
Does PFE Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Stable to Eroding
Moat Sources
4 Identified
Pfizer's formidable R&D engine, vast global infrastructure, and established brand facilitate a wide and durable moat. However, the continuous cycle of patent expirations necessitates constant innovation to maintain its competitive edge.
Moat Erosion Risks
- •Expiration of patents on blockbuster drugs (patent cliff risk)
- •Intensified competition from biosimilars and generics
- •Regulatory changes impacting drug pricing or market access
- •Failure to successfully develop and commercialize new pipeline assets
PFE Competitive Moat Analysis
Sign up to see competitive advantages
PFE Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (Predominantly viewed as a stable dividend-paying stock rather than a high-growth investment)
Institutional Sentiment
Positive (72% institutional ownership with major holders like Vanguard and BlackRock; Starboard Value's activist stake signals belief in value unlock and operational improvements)
Insider Activity (Form 4)
Starboard Value acquired a $1 billion stake in late 2024–early 2025, advocating for strategic focus on oncology and cost savings.
Options Flow
Normal options activity (No specific unusual activity identified in search results).
Earnings Intelligence
Next Earnings
2026-05-05
Surprise Probability
Medium
Historical Earnings Pattern
For large-cap pharma, stock reactions to earnings are typically moderate unless there are significant beats/misses, major pipeline news, or guidance revisions.
Key Metrics to Watch
Competitive Position
Top Competitor
JNJ
Market Share Trend
Stable overall, with strategic acquisitions (Seagen) aimed at gaining market share in specific high-growth therapeutic areas like oncology.
Valuation vs Peers
Likely trading at a discount or comparable to peers facing patent cliffs, but potentially at a premium for its robust pipeline and dividend yield.
Competitive Advantages
- •Extensive R&D capabilities and a diversified pipeline
- •Global manufacturing and distribution network
- •Strong brand recognition and established market presence
- •Broad therapeutic portfolio mitigating individual drug risks
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PFE Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (May 5, 2026)
- •Regulatory submissions for Lyme disease vaccine (PF-07307405)
- •Continued progress on $4 billion annual cost savings target by end of 2025
Medium-Term (6-18 months)
- •Potential new drug approvals from the strengthened oncology pipeline (post-Seagen)
- •Phase 3 data for atirmociclib in breast cancer
- •Expansion of HYMPAVZI indication in European markets
Long-Term (18+ months)
- •Sustained growth in oncology and vaccine segments
- •Successful integration and synergy realization from Seagen acquisition
- •Pipeline replenishment and innovation offsetting patent cliffs
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PFE?
- ✓
Consistent positive updates on late-stage pipeline assets and regulatory approvals
- ✓
Evidence of stabilization or growth in overall revenue and EPS guidance
- ✓
Successful achievement and impact of targeted cost savings from activist pressure
Bull Case Analysis
See what could go right with Premium
Competing with PFE
See how Pfizer Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Pfizer Inc PFE | $161.1B | 0.2 | 20.2 | $17.6B | 12.4% | -1.7% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
UnitedHealth Group Inc UNH | $300.6B | 0.5 | 17.3 | — | — | — | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Pfizer Inc Makes Money
Pfizer generates revenue by discovering, developing, manufacturing, and globally marketing a diverse portfolio of prescription medicines and vaccines. Its core business model relies on intellectual property (patents) to protect innovative drugs, allowing it to sell these high-margin products to healthcare providers, governments, and patients worldwide through its extensive distribution network. The company continuously invests in research and development to bring new therapies to market, offsetting revenue declines from older drugs losing patent exclusivity.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Pfizer Inc (PFE)?
As of April 6, 2026, Pfizer Inc has a DVR Score of 0.2 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Pfizer Inc?
Pfizer Inc's market capitalization is approximately $161.1B. The company operates in the Healthcare sector within the Drug Manufacturers - General industry.
What ticker symbol does Pfizer Inc use?
PFE is the ticker symbol for Pfizer Inc. The company trades on the NYQ.
What is the risk level for PFE stock?
Our analysis rates Pfizer Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PFE?
Pfizer Inc currently has a price-to-earnings (P/E) ratio of 20.2. This is in line with broader market averages.
Does Pfizer Inc pay a dividend?
Yes, Pfizer Inc pays a dividend with a current yield of approximately 6.22%.
Is Pfizer Inc's revenue growing?
Pfizer Inc has reported revenue growth of -1.7%. Revenue has been declining, which warrants closer examination.
Is PFE stock profitable?
Pfizer Inc has a profit margin of 12.4%. The company is profitable but margins are modest.
How often is the PFE DVR analysis updated?
Our AI-powered analysis of Pfizer Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 6, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PFE (Pfizer Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.